Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Longymickshort, I must admit that what you state below is air-tight logic (even if delivered via caveman-osmosis - lol).
GRCU common O/S shs stability impressive.
When performing an analysis of an OTC company, most areas of discussion are highly subjective. Since this is the case, any objective measures that exist become critically important in the overall assessment of future potential.
Here's an objective evaluation of one of the most success determinant measures for an OTC company... the growth of the common shares outstanding since inception.
'On February 25, 2014, control of the Company was transferred from Gregory Lykiardopoulos to Green Cures, Inc., a California corporation, pursuant to a Stock Purchase Agreement entered on February 5,2014.'
There have been three quarterly filings, since Green Cures took over the ticker (the qtrs ended March, June and September). The total common shares outstanding, reported on these filings, is detailed below.
Total common shares outstanding: 1,633,695,597 as of: 4/23/14 (filing for the quarter ended 3/31/2014, filed on 5/15/2014)
Total common shares outstanding: 1,636,233,097 as of: 07/28/14 (filing for the quarter ended 6/30/2014, filed on 8/14/2014) - less than a one percent increase in common shares outstanding, over the quarter
Total common shares outstanding: 1,660,316,671 as of: 11/14/14 (filing for the most recently reported period, ended 9/30/2014) - less than a two percent increase in common shares outstanding, over the quarter
In the fog of the OTC, some things are truly telling about the essence of a company. As is detailed above, total common shares outstanding for Green Cures has increased by about 2% through three fiscal quarters.
So here's the objective question I would ask, for those that have had numerous positions in other OTC companies in your trading/investing history. How many of those companies have a similar history of outstanding common share increases as I have detailed above for Green Cures (GRCU)?
As I've opined before, 'Investment wisdom could be defined as the ability to recognize the building of a future empire, even as the earliest bricks are being laid.' I believe those words hold a fundamental truth.
As always, simply my opinion.
GRCU
Well stated addition to my point, DMOST. I was also going to mention that some of the OTC companies that yielded the largest returns for me, had quit producing any financial reports (gone dark).
What it shows it that the correlation between the strength/level of financial filings, and the stock's share price performance, are loosely bound at best.
As always, simply my opinion.
Every single one of Enron's annual financial statements were audited. As a matter of fact, they were audited by one of the biggest accounting firms that existed at the time - Arthur Andersen. Both Enron and Arthur Andersen's accounting division were subsequently shut down for failures and improprieties.
Your point regarding the lack of audited financials is surely weakened, given the above example. That is not to say that there is not a real value, in a general sense, to having financial statements audited by an objective entity. An outside audit increases confidence in the numbers, but it does not provide absolute assurances.
Please also note, though, that it is ordinary and customary (for firms that have their financial statements audited), to have them done on the full year only, not the individual quarters.
Nice work, mrcheap. IMO, we are on the verge of a violent and massive upward movement in the share price of GRCU.
GRCU
Scaling in and scaling out...
There are a number of effective strategies that can be employed to hedge (reduce) risk. One strategy which has been proven highly effective is scaling in and scaling out. In the past, I was one of those traders/investors that was either all in or all out of a security. I can't really tell you why that was my approach in the past. I can only tell you that was the way it was for me, for a very long time.
That approach (buying all of the shares I would ever own in one transaction, and exiting from all shares in one transaction) proved to be difficult mentally, and undoubtedly hurt my overall portfolio performance. For example, I would own an OTC stock that would be up 10 to 15x, but would be very hesitant to sell because I knew that if/when I sold it all, if it continued to climb, I would have severe regrets. Conversely, when I would establish a position in an OTC security, I would take a huge hit if my timing was off because I bought all of my shares at that one price.
Over the past couple of years, I have learned that a much better approach (and one that is also recommended by portfolio mgr extraordinaire Jim Cramer of 'Mad Money' fame) is to divide your buys or sells into steps, at various prices. And better yet, to dollar cost average at each of those steps (meaning a fixed dollar amount rather than a fixed share amount). This allows for a lower cost per share, and cumulative avg share cost (and a greater quantity of shares), should the security decline in price after your initial purchase. And should the security begin to increase after the initial purchase, you probably won't mind too much spending a bit more on the subsequent purchases, because paper gains have been realized on the earlier (and cheaper) purchases of that security.
Exiting a security, in the same step-like fashion, makes it easier mentally to let go of shares while the security price still has upside (because you have not made an all-or-nothing gamble at the singular price).
It is for these reasons that I now use the scaling in and scaling out approach, rather than a complete entry into a security or exit out of a security. I feel that overall, it works well, and that is why I used this approach while initially accumulating my BTZO shares.
As always, simply my opinion.
BTZO
**Although I know that many are already using this approach, there are probably others that are not, and it is for the benefit of those people that I have posted this info.
When performing an analysis of an OTC company, most areas of discussion are highly subjective. Since this is the case, any objective measures that exist become critically important in the overall assessment of future potential.
Here's an objective evaluation of one of the most success determinant measures for an OTC company... the growth of the common shares outstanding since inception.
'On February 25, 2014, control of the Company was transferred from Gregory Lykiardopoulos to Green Cures, Inc., a California corporation, pursuant to a Stock Purchase Agreement entered on February 5,2014.'
There have been three quarterly filings, since Green Cures took over the ticker (the qtrs ended March, June and September). The total common shares outstanding, reported on these filings, is detailed below.
Total common shares outstanding: 1,633,695,597 as of: 4/23/14 (filing for the quarter ended 3/31/2014, filed on 5/15/2014)
Total common shares outstanding: 1,636,233,097 as of: 07/28/14 (filing for the quarter ended 6/30/2014, filed on 8/14/2014) - less than a one percent increase in common shares outstanding, over the quarter
Total common shares outstanding: 1,660,316,671 as of: 11/14/14 (filing for the most recently reported period, ended 9/30/2014) - less than a two percent increase in common shares outstanding, over the quarter
In the fog of the OTC, some things are truly telling about the essence of a company. As is detailed above, total common shares outstanding for Green Cures has increased by about 2% through three fiscal quarters.
So here's the objective question I would ask, for those that have had numerous positions in other OTC companies in your trading/investing history. How many of those companies have a similar history of outstanding common share increases as I have detailed above for Green Cures (GRCU)?
As I've opined before, 'Investment wisdom could be defined as the ability to recognize the building of a future empire, even as the earliest bricks are being laid.' I believe those words hold a fundamental truth.
As always, simply my opinion.
GRCU
When performing an analysis of an OTC company, most areas of discussion are highly subjective. Since this is the case, any objective measures that exist become critically important in the overall assessment of future potential.
Here's an objective evaluation of one of the most success determinant measures for an OTC company... the growth of the common shares outstanding since inception.
'On February 25, 2014, control of the Company was transferred from Gregory Lykiardopoulos to Green Cures, Inc., a California corporation, pursuant to a Stock Purchase Agreement entered on February 5,2014.'
There have been three quarterly filings, since Green Cures took over the ticker (the qtrs ended March, June and September). The total common shares outstanding, reported on these filings, is detailed below.
Total common shares outstanding: 1,633,695,597 as of: 4/23/14 (filing for the quarter ended 3/31/2014, filed on 5/15/2014)
Total common shares outstanding: 1,636,233,097 as of: 07/28/14 (filing for the quarter ended 6/30/2014, filed on 8/14/2014) - less than a one percent increase in common shares outstanding, over the quarter
Total common shares outstanding: 1,660,316,671 as of: 11/14/14 (filing for the most recently reported period, ended 9/30/2014) - less than a two percent increase in common shares outstanding, over the quarter
In the fog of the OTC, some things are truly telling about the essence of a company. As is detailed above, total common shares outstanding for Green Cures has increased by about 2% through three fiscal quarters.
So here's the objective question I would ask, for those that have had numerous positions in other OTC companies in your trading/investing history. How many of those companies have a similar history of outstanding common share increases as I have detailed above for Green Cures (GRCU)?
As I've opined before, 'Investment wisdom could be defined as the ability to recognize the building of a future empire, even as the earliest bricks are being laid.' I believe those words hold a fundamental truth.
As always, simply my opinion.
GRCU
Excellent points, sweet crude. And to your point regarding the market cap, I know we've all seen OTC companies, with far less going for them, run deep into the 10s of millions of dollars in market cap (albeit briefly, at times).
As always, simply my opinion.
Thanks CA$HBAG$. The OTC market is not for everybody. Some might say that it is precisely what antacid tablets were developed for...
According to info posted here (based upon transfer agent gathered info for FPFI(D)), the total outstanding share count was:
Approx 7.483 million on Jan 22nd, 2014
Approx 7.855 million on Feb 2nd, 2014
and now, according to todays PR, stands at
Approx 8.227 million.
That equates to an O/S increase of about 10% over the past 2 and a half weeks, or a total of 744k shares.
Taking into account that this has been the busiest PR/news cycle for FPFI(D) in a while, I think that most would agree that dilution has been held, thus far, to a manageable level. If they can continue to keep dilution to a minimum, there could be much more upside still to come.
As always, simply my opinion.
FPFI(D)
In the ocean of the OTC,
the waters, they are rough.
To navigate the crashing waves,
the skin, it must be tough.
Glimmers of hope, follow despair
projections a dime-a-dozen.
A million made, a million lost,
so claims a distant cousin.
So then, the question does remain
why are we all here.
Because volatility is our friend,
or so it would appear. -Odessa99
Given a successful launch of the Rico Suave hemp-infused beverage line, the potential upside (IMO) for Green Cures is enormous.
GRCU
Watching a portfolio balance suffer, as a stock declines in value, is never an easy thing, ' A Star should shine'. And in the OTC, it is all too common of an occurrence.
And even more difficult, is making the tough decision to cut one's losses, and the timing of such a decision. It is a personal decision that is often dependent upon one's own risk tolerance, and their ability to absorb such a loss. Also to be considered is the opportunity cost of keeping the money tied up for an extended period of time, while alternative trading and investing opportunities are present elsewhere.
As to Green Cures, there have been several missteps along the way, while they built the business from scratch. Thus far, this has undoubtedly hindered the ability of the stock to hold on to a higher price level. I hold the believe that they have now worked out many of the early kinks, and that they are on the verge of accomplishing a great deal more than they have to date.
For that reason, I continue to maintain my long position on GRCU. But I can not fault anyone who chooses to exit, in an effort to eliminate the risk of further decline (which is always present, and especially so in the OTC). Best of luck in your trading and investing.
As always, simply my opinion.
GRCU
From dark to dawn
the saying goes.
It happens all
too often.
When this
wraps up
a jet I'll own
for me to get
aloft in. - Odessa99
The eventual upside in GRCU will astonish some, but I have been a believer from the start.
GRCU
RSI now showing an extremely oversold condition (the lowest level, thus far, in 2015), as well as 5 red days in a row (see chart below). I think that the odds of a nice green close are fairly high.
Additionally, the last time it dipped into the mid to upper .004s (and below the 50 day simple moving avg), it bounced up nicely.
As always, simply my opinion.
GRCU
I haven't defended the company's actions. As you know, I have now gone on the record several times agreeing that it is misleading, at best.
But to assert that there are never patents issued once a patent application receives 'final rejection', would also be misleading, when one truly understands the entire patent process.
As always, simply my opinion.
You have reminded me of a fortune (from fortune cookie) I once received, a long time ago. It said (paraphrasing) 'He who thinks he knows all, knows all he will ever know'.
You may be interested in the link below, from law360:
http://www.law360.com/articles/468230/uspto-s-final-rejection-of-a-patent-isn-t-so-final
The linked article is titled 'USPTO's Final Rejection Of A Patent Isn't So Final'
The article begins 'A final U.S. Patent and Trademark Office action rejecting a patent application may appear to sound the death knell for your company’s patent application. Fortunately, in patent prosecution, as with many mistakes in life, “final” does not really mean “final” — you still have opportunities to “make amends” and overcome the problem in various ways.'
Please also note that although a final rejection does always spell the end for a potential patent, I still agree that stating 'patent pending' for a submitted patent which has received a final rejection is misleading at best, and does not sit well with me.
As always, simply my opinion.
Please refer to my post, #216235, later in the evening.
link:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110564955
More than 99% buys at the ask so far this morning. Just added more .0002s.
QASP
I'll take the compliment, even though it seems you may be implying that RickNagra and I are one-in-the-same. I assure you that is not the case.
Best of luck to you with your investments, especially GRCU.
Nice work, jzgeorge.
The GRCU long-term investors will have our day here, and it is not far off, IMO.
I didn't think this day would come, but I agree with you 100% (as to your sentiment expressed below).
Not necessarily 100% wrong, as 'final rejection' is not always 'final'. Please see the information below, directly from the US Patent and trademark office:
"35 U.S.C. 134 Appeal to the Patent Trial and Appeal Board.
(a) PATENT APPLICANT.— An applicant for a patent, any of whose claims has been twice rejected, may appeal from the decision of the primary examiner to the Patent Trial and Appeal Board, having once paid the fee for such appeal.
(b) PATENT OWNER.— A patent owner in a reexamination may appeal from the final rejection of any claim by the primary examiner to the Patent Trial and Appeal Board, having once paid the fee for such appeal."
link:
http://www.uspto.gov/web/offices/pac/mpep/s1204.html
"After the examiner has rejected claims twice the examiner has the authority to make the rejections final. Final rejection, however, is not so final. There is still an opportunity to amend and make changes. You have a right to amend to cancel claims, place claims in better condition for appeal, or amend the claims if you are going to adopt a suggestion of the Examiner that would make a claim patentable. No other changes will be permitted by the Patent Examiner after Final Rejection. Thus, Final Rejection really signifies the entrance into the end game of a prosecution, whereby the prosecution of the application is winding down to a conclusion."
link:
http://www.ipwatchdog.com/2014/03/15/an-overview-of-the-u-s-patent-process-2/id=48506/
If those Final rejections (that you've posted) cover all of the patent applications that Dr. Trent Jones had with the USPTO, then he absolutely should not be claiming a 'patent pending' status on anything he has invented. I can not disagree with that.